NYSE - Nasdaq Real Time Price USD

Ginkgo Bioworks Holdings, Inc. (DNA)

7.76
-0.11
(-1.40%)
At close: May 9 at 4:00:02 PM EDT
7.75
-0.01
(-0.13%)
After hours: May 9 at 7:59:57 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
237,417
227,043
251,455
477,706
313,837
Cost of Revenue
47,393
44,548
54,005
204,216
129,690
Gross Profit
190,024
182,495
197,450
273,490
184,147
Operating Expense
583,444
670,222
965,646
2,482,442
2,012,614
Operating Income
-393,420
-487,727
-768,196
-2,208,952
-1,828,467
Net Non Operating Interest Income Expense
32,888
38,518
57,124
20,156
-1,536
Other Income Expense
-111,965
-98,299
-181,868
67,397
-8,119
Pretax Income
-472,497
-547,508
-892,940
-2,121,399
-1,838,122
Tax Provision
-422
-479
-71
-15,027
-1,480
Net Income Common Stockholders
-471,611
-547,029
-892,869
-2,104,929
-1,888,662
Diluted NI Available to Com Stockholders
-471,611
-547,029
-892,869
-2,104,929
-1,888,662
Basic EPS
-8.91
-10.54
-18.37
-50.00
-54.00
Diluted EPS
-8.91
-10.54
-18.37
-50.00
-55.60
Basic Average Shares
52,927.18
51,894.64
48,610.51
41,976.54
33,996.22
Diluted Average Shares
52,927.18
51,894.64
48,610.51
41,995.97
34,009.33
Total Operating Income as Reported
-470,723
-559,757
-864,406
-2,208,952
-1,828,467
Total Expenses
630,837
714,770
1,019,651
2,686,658
2,142,304
Net Income from Continuing & Discontinued Operation
-472,075
-547,029
-892,869
-2,104,929
-1,830,047
Normalized Income
-362,641.83
-444,962.17
-704,512.98
-2,207,719.68
-1,900,874.10
Interest Income
32,982
38,612
57,217
20,262
837
Interest Expense
--
94
93
106
2,373
Net Interest Income
32,888
38,518
57,124
20,156
-1,536
EBIT
-453,107
-547,414
-892,847
-2,121,293
-1,835,749
EBITDA
-387,590
-484,394
-822,340
-2,078,741
-1,806,673
Reconciled Cost of Revenue
47,393
44,548
54,005
204,216
129,690
Reconciled Depreciation
65,517
63,020
70,507
42,552
29,076
Net Income from Continuing Operation Net Minority Interest
-472,075
-547,029
-892,869
-2,104,929
-1,830,047
Total Unusual Items Excluding Goodwill
-109,531
-102,169
-188,371
103,524
70,898
Total Unusual Items
-109,531
-102,169
-188,371
103,524
70,898
Normalized EBITDA
-278,059
-382,225
-633,969
-2,182,265
-1,877,571
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-97.83
-102.17
-14.98
733.32
70.90
12/31/2021 - 4/19/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NTLA Intellia Therapeutics, Inc.
8.12
-1.93%
 
BEAM Beam Therapeutics Inc.
17.41
+0.93%
 
RXRX Recursion Pharmaceuticals, Inc.
4.3300
-1.37%
 
CRSP CRISPR Therapeutics AG
35.62
-1.44%
 
IOVA Iovance Biotherapeutics, Inc.
1.7500
-44.79%
 
ABCL AbCellera Biologics Inc.
2.0300
+1.00%
 
SRPT Sarepta Therapeutics, Inc.
36.27
-0.68%
 
EDIT Editas Medicine, Inc.
1.4500
+4.32%
 
VERV Verve Therapeutics, Inc.
4.2300
-5.58%
 
IBRX ImmunityBio, Inc.
2.0700
-0.96%